C. Sert-Langeron

Effects of initiation and titration of a single pre‐prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6‐month ‘proof‐of‐concept' study

D. R. Owens, Stephen D. Luzio, C. Sert-Langeron et al. · Diabetes Obesity and Metabolism · 2011 · 97 citations · Full text

Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial

Arianne C. van Bon, Bruce W. Bode, C. Sert-Langeron et al. · Diabetes Technology & Therapeutics · 2011 · 94 citations

Insulin Glulisine Has a Faster Onset of Action Compared with Insulin Aspart in Healthy Volunteers

Sabine Arnolds, Klaus Rave, Ulrike Hövelmann et al. · Experimental and Clinical Endocrinology & Diabetes · 2010 · 41 citations

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes

Geremia B. Bolli, Stephen D. Luzio, Stefania Marzotti et al. · Diabetes Obesity and Metabolism · 2010 · 37 citations · Full text

Severe resistance to insulin and insulin-like growth factor-I in cells from a patient with leprechaunism as a result of two mutations in the tyrosine kinase domain of the insulin receptor

Christèle Desbois‐Mouthon, Claude Danan, Serge Amselem et al. · Metabolism · 1996 · 36 citations

Insulin Resistance, Metabolic Syndrome, Insulin Signaling +15